This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Fudan University, The Ohio State University, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2015.
Company Filing History:
1 out of 224 
1 out of 1,575 
1 out of 3,690 
Years Active: 2015
Title: Innovations of Hui-chuan Sun in Hepatocellular Carcinoma Research.
Introduction
Hui-chuan Sun is a notable inventor based in Shanghai, China. She has made significant contributions to the field of hepatocellular carcinoma (HCC) research. Her work focuses on the use of microRNA-26 as a predictive marker for HCC and its responsiveness to therapy.
Latest Patents
Hui-chuan Sun holds a patent titled "Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy." This patent reveals that the expression of microRNA-26 is decreased in HCC tumor tissue compared to non-cancerous tissue. A low level of microRNA-26 is associated with poor clinical outcomes. Furthermore, it is disclosed that low expression levels of microRNA-26 correlate with a favorable response to interferon (IFN)-α therapy in HCC patients. The patent provides methods for predicting clinical outcomes and selecting patients for therapy based on microRNA-26 expression levels.
Career Highlights
Hui-chuan Sun has worked with prestigious institutions, including Fudan University and the United States Department of Health and Human Services. Her research has contributed to advancements in understanding HCC and improving treatment options for patients.
Collaborations
Hui-chuan Sun has collaborated with esteemed colleagues such as Carlo M. Croce and Xin Wei Wang. These collaborations have further enhanced her research and its impact on the medical community.
Conclusion
Hui-chuan Sun's innovative work in the field of hepatocellular carcinoma research highlights the importance of microRNA-26 as a predictive marker and its potential in therapy selection. Her contributions continue to influence the landscape of cancer research and treatment.